Resources Repository
-
OrganizationWeb Portal 2024ISPOR
Founded in 1995 as an international multidisciplinary professional membership society, the International Society for Pharmacoeconomics …
Founded in 1995 as an international multidisciplinary professional membership society, the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) exists to advance the policy, science, and practice of pharmacoeconomics (health economics) and health outcomes research. ISPOR publishes Value in Health, which contains original research articles in the areas of economic evaluation, outcomes research, and conceptual, methodological, and health policy articles. Beyond health economics and outcomes research resources, tools of ISPOR include strategic initiatives, publications, and member…
Priority Setting/Ethics | Technology Assessment | Cost-Effectiveness Analysis | Health Outcomes | Value of Information | Health/Medicine | Preferences/Values | Costing Methods | Mathematical Models | Operations Research | Infectious Diseases | Maternal/Reproductive Health | Child/Nutrition | Chronic Disease/Risk | Health Systems | Policy/Regulation | Business/Industry | Economics/Finance | Science/Technology | Global -
ArticlePublication 2021Health Opportunity Cost Threshold for CEA in the U.S.
Using a modeled cohort of 100,000 individuals in the United States with private health insurance, …
Using a modeled cohort of 100,000 individuals in the United States with private health insurance, the authors simulated the short-term mortality and morbidity resulting from increased premium related cancelation of insurance coverage. The authors used this model to estimate cost-effectiveness thresholds, in dollars per quality-adjusted life year (QALY) gained based on health opportunity costs. They reported the number of persons who dropped insurance coverage, resulting number of additional deaths and QALYs lost from mortality and…
Priority Setting/Ethics | Microsimulation | Cost-Effectiveness Analysis | Health Outcomes | Health/Medicine | Evidence Synthesis | Health Systems | Policy/Regulation | North America -
ArticlePublication 2017Reduced Burden of Childhood Diarrheal Diseases through Increased Access to Water and Sanitation in India: Modeling Analysis
This analysis estimates the health and economic benefits of scaling up the coverage of piped …
This analysis estimates the health and economic benefits of scaling up the coverage of piped water and improved sanitation to a near-universal 95% level among Indian households. The authors used an agent-based microsimulation platform, IndiaSim, to model disease progression and individual healthcare-seeking behavior in India, and use ECEA to estimate health and economic outcomes over time. They found that scaling up access to piped water and improved sanitation could avert 43,352 diarrheal episodes and 68…
Priority Setting/Ethics | Microsimulation | Cost-Effectiveness Analysis | Health Outcomes | Health/Medicine | Costing Methods | Child/Nutrition | Social Determinants | Environmental Health | Economics/Finance | Energy/Engineering | Science/Technology | Asia & Pacific -
OrganizationWeb Portal 2024International Decision Support Initiative (iDSI)
The International Decision Support Initiative (iDSI) is a global network of health, policy and economic …
The International Decision Support Initiative (iDSI) is a global network of health, policy and economic expertise, working to achieve Universal Health Coverage and The Health Sustainable Development Goal (SDG 3). They are committed to robust evidence, analysis and decision-making that policymakers, funders and researchers can use to balance trade-offs between different policy options and model potential results to make the best choice available. They support countries to make better decisions about how much public money…
Priority Setting/Ethics | Technology Assessment | Cost-Effectiveness Analysis | Health Outcomes | Health/Medicine | Costing Methods | Health Systems | Policy/Regulation | Economics/Finance | Government/Law | Global -
OrganizationWeb Portal 2024Institute for Clinical and Economic Review (ICER)
ICER is a non-profit organization that evaluates evidence on a range of topics including the value …
ICER is a non-profit organization that evaluates evidence on a range of topics including the value of medical tests, treatments and delivery system innovations and moves that evidence into action to improve the health care system. To accomplish this goal ICER performs analyses on effectiveness and costs, supports specific programs, and develops reports using innovative methods that make it easier to translate evidence into decisions that can align efforts to use evidence to drive improvements in both…
Priority Setting/Ethics | Technology Assessment | Cost-Effectiveness Analysis | Value of Information | Health/Medicine | Preferences/Values | Evidence Synthesis | Infectious Diseases | Chronic Disease/Risk | Mental Health | Health Systems | Business/Industry | Economics/Finance | Government/Law | Science/Technology | North America | Europe -
ReviewPublication 2021Review of Web-Based Tools for Value-of-Information Analysis
Value-of-information analysis (VOI) is an analytic approach used to inform research priorities, guide clinical trial …
Value-of-information analysis (VOI) is an analytic approach used to inform research priorities, guide clinical trial design, and provide information for decisions about reimbursement. The authors review existing web-based tools to facilitate VOI calculations. These include Sheffield Accelerated Value of Information (SAVI), the web interface to the BCEA (Bayesian Cost-Effectiveness Analysis) R package (BCEAweb), Rapid Assessment of Need for Evidence (RANE), and Value of Information for Cardiovascular Trials and Other Comparative Research (VICTOR).
Priority Setting/Ethics | Cost-Effectiveness Analysis | Value of Information | Health/Medicine | Decision Theory | Economics/Finance -
ArticlePublication 2016Health and Economic Benefits of Public Financing of Epilepsy Treatment in India
This study uses extended cost-effectiveness analysis (ECEA) to evaluate the impact of three scenarios of …
This study uses extended cost-effectiveness analysis (ECEA) to evaluate the impact of three scenarios of publicly financed national epilepsy programs in India that provide (1) first line antiepilepsy drugs (AEDs), (2) first- and second-line AEDs, and (3) first- and second-line AEDs and surgery. Outcome measures include disability-adjusted life years (DALYs) averted, and cost per DALY averted. Economic benefit measures estimated include out-of-pocket (OOP) expenditure averted and money-metric value of insurance. All three scenarios represent a…
Priority Setting/Ethics | Microsimulation | Cost-Effectiveness Analysis | Health/Medicine | Chronic Disease/Risk | Economics/Finance | Asia & Pacific -
ArticlePublication 2018Equity Impact Vaccines May Have on Averting Deaths and Medical Impoverishment
In this analysis, authors estimated the number of deaths averted and the number of cases …
In this analysis, authors estimated the number of deaths averted and the number of cases of medical impoverishment averted of ten antigens and their corresponding vaccines across income quintiles for forty-one low- and middle-income countries. The study found that vaccines administered between 2016 and 2030 would prevent 36 million deaths. Vaccines will have the greatest impact on reducing cases of poverty caused by hepatitis B, helping an estimated 14 million people avoid medical impoverishment. An…
Priority Setting/Ethics | Cost-Effectiveness Analysis | Health Outcomes | Health/Medicine | Costing Methods | Mathematical Models | Infectious Diseases | Child/Nutrition | Global Governance | Economics/Finance | Science/Technology | Sub-Saharan Africa | Middle East & North Africa | Asia & Pacific -
ArticlePublication 2017Cost-Effectiveness of Intensive versus Standard Blood-Pressure Control
Based on data from the Systolic Blood Pressure Intervention Trial (SPRINT), the authors of this …
Based on data from the Systolic Blood Pressure Intervention Trial (SPRINT), the authors of this article compared the cost-effectiveness of intensive versus standard control in adults at high risk for cardiovascular disease who received intensive systolic blood-pressure control. A microsimulation model was used to project lifetime costs of treatment and monitoring, cardiovascular disease events and subsequent treatment costs, treatment-related risks of serious adverse events and subsequent costs, and quality-adjusted life-years (QALYs) for the two strategies.…
Microsimulation | Cost-Effectiveness Analysis | Health Outcomes | Health/Medicine | Chronic Disease/Risk | North America